GlobalResearch and clinical trials
In Alagille syndrome, maralixibat reduced fatty skin deposits in a pooled analysis of two trials
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
Fatty deposits in the skin were studied in children with Alagille syndrome. Data from 63 children in two clinical trials were evaluated together. At the start, 43% of the children had these deposits. With maralixibat, the deposits and cholesterol decreased over 96 weeks.
What does it mean for patients and families?
This study is an analysis done afterward and includes a limited number of children. The study's authors included people from the drug company. Treatment decisions are made with the doctor.
Source
Scientific paper: Maralixibat Improves Xanthomas and Hypercholesterolemia in Children with Alagille Syndrome: A Post Hoc Integrated Analysis From Two Clinical Trials. The Journal of Pediatrics, 2026. DOI: 10.1016/j.jpeds.2026.115108 · PubMed 42002216
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Alagille syndrome
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.